Local innate immune responses in the vaccine adjuvant-injected muscle

Clinical and Translational Immunology

Volumn 5, Issue 4, 2016, Pages

  Liang, Frank ^a   Loré, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; TOLL LIKE RECEPTOR; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CELL ACTIVATION; CELL HOMING; EMULSION; HUMAN; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; INNATE IMMUNITY; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 85049894774     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2016.19     Document Type: Review

References (59)

1. Kunzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kursteiner O et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009; 27: 3561–3567.
2. Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis 2012; 206: 1069–1077.
3. Liang F, Ploquin A, Hernandez JD, Fausther-Bovendo H, Lindgren G, Stanley D et al. Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. J Immunol Methods 2015; 425: 69–78.
4. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492–503.
5. Smed-Sorensen A, Lore K. Targeting dendritic cells for improved HIV-1 vaccines. Adv Exp Med Biol 2013; 762: 263–288.
6. Harrison WT. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health 1935; 25: 298–300.
7. Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J 2012; 26: 1272–1279.
8. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122–1126.
9. Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008; 181: 3755–3759.
10. Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008; 38: 2085–2089.
11. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183: 4403–4414.
12. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869–882.
13. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–241.
14. Goto N, Kato H, Maeyama J, Shibano M, Saito T, Yamaguchi J et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997; 15: 1364–1371.
15. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011; 17: 996–1002.
16. McKee AS, Burchill MA, Munks MW, Jin L, Kappler JW, Friedman RS et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci USA 2013; 110: E1122–E1131.
17. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424–2435.
18. Bihari I, Panczel G, Kovacs J, Beygo J, Fragapane E. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol 2012; 19: 1943–1948.
19. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28: 1740–1745.
20. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201: 1644–1653.
21. Tengerdy RP, Lacetera NG. Vitamin E adjuvant formulations in mice. Vaccine 1991; 9: 204–206.
22. Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA 2011; 108: 11169–11174.
23. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008; 105: 10501–10506.
24. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29: 1812–1823.
25. Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA 2013; 110: 21095–21100.
26. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29: 2461–2473.
27. Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193: 1920–1930.
28. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186–6197.
29. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995; 6: 277–296.
30. Lore K, Karlsson Hedestam GB. Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 2009; 4: 441–446.
31. Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol 2008; 125: 18–30.
32. Prince LR, Whyte MK, Sabroe I, Parker LC. The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011; 11: 397–403.
33. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10: 471–486.
34. Moorthy VS, Okwo-Bele JM. Final results from a pivotal phase 3 malaria vaccine trial. Lancet 2015; 386: 5–7.
35. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087–2096.
36. Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults 50 years of age. J Infect Dis 2013; 208: 1953–1961.
37. Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K et al. Identification of QS-21 as an Inflammasome-activating molecular component of saponin adjuvants. J Biol Chem 2016; 291: 1123–1136.
38. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses 2008; 2: 41–51.
39. Boyd JH, Divangahi M, Yahiaoui L, Gvozdic D, Qureshi S, Petrof BJ. Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 2006; 74: 6829–6838.
40. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013; 31: 3363–3369.
41. Neeland MR, Elhay MJ, Nathanielsz J, Meeusen EN, de Veer MJ. Incorporation f CpG into a liposomal vaccine formulation increases the maturation of antigen-loaded dendritic cells and monocytes to improve local and systemic immunity. J Immunol 2014; 192: 3666–3675.
42. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200: 337–346.
43. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 2001; 31: 2910–2918.
44. Lu F, Hogenesch H. Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. Vaccine 2013; 31: 3979–3986.
45. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180: 5402–5412.
46. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17: 479–487.
47. Jounai N, Kobiyama K, Takeshita F, Ishii KJ. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol 2012; 2: 168.
48. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; 2010.
49. Jacobson LS, Lima H Jr, Goldberg MF, Gocheva V, Tsiperson V, Sutterwala FS et al. Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants. J Biol Chem 2013; 288: 7481–7491.
50. Rose WA 2nd, Okragly AJ, Patel CN, Benschop RJ. IL-33 released by alum is responsible for early cytokine production and has adjuvant properties. Sci Rep 2015; 5: 13146.
51. Shen SS, Yang YW. Dynamics of antigen delivery and the functional roles of L121-adjuvant. Vaccine 2015; 33: 4341–4348.
52. Kawai T, Akira S. Signaling to NF-kappaB by toll-like receptors. Trends Mol Med 2007; 13: 460–469.
53. Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 2012; 147: 55–62.
54. Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K et al. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 2004; 78: 11152–11160.
55. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 2012; 13: 170–180.
56. Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 2011; 23: 317–326.
57. Yang CW, Strong BS, Miller MJ, Unanue ER. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol 2010; 185: 2927–2934.
58. Gujer C, Sundling C, Seder RA, Karlsson Hedestam GB, Lore K. Human and rhesus plasmacytoid dendritic cell and B-cell responses to toll-like receptor stimulation. Immunology 2011; 134: 257–269.
59. Kwissa M, Nakaya HI, Oluoch H, Pulendran B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 2012; 119: 2044–2055.